JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

Kodu・Aktsiate loetelu・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Suletud

8.12 -0.12

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.9399999999999995

Max

8.51

Põhinäitajad
By Trading Economics
Sissetulek	453K -27M
Kasumimarginaal	-2,027.003
Töötajad	81
EBITDA	408K -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+50.67% upside

Turustatistika
By TradingEconomics
Turukapital	266M 459M
Eelmine avamishind	8.24
Eelmine sulgemishind	8.12

Ventyx Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. nov 2025, 23:57 UTC

Tulu

Naver's Third-Quarter Earnings Rose on AI Push

4. nov 2025, 23:10 UTC

Omandamised, ülevõtmised, äriostud

Kennedy-Wilson Gets Acquisition Proposal From CEO, Fairfax Financial

4. nov 2025, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. nov 2025, 23:48 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stock Weakness -- Market Talk

4. nov 2025, 23:37 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

4. nov 2025, 23:30 UTC

Tulu

Itau Unibanco 3Q Net BRL33.7B >ITUB

4. nov 2025, 23:25 UTC

Tulu

Naver 3Q Net Profit Beat FactSet-Compiled Consensus

4. nov 2025, 23:25 UTC

Tulu

Naver 3Q Net KRW734.70B Vs. Net KRW530.10B >035420.SE

4. nov 2025, 23:24 UTC

Tulu

Naver 3Q Oper Pft KRW570.60B Vs. Pft KRW525.30B >035420.SE

4. nov 2025, 23:23 UTC

Tulu

Naver 3Q Rev KRW3.138T Vs. KRW2.716T >035420.SE

4. nov 2025, 23:06 UTC

Tulu

Review & Preview: Tech Check -- Barrons.com

4. nov 2025, 22:52 UTC

Tulu

AMD Reports Sharply Higher Profits, Sales -- 3rd Update

4. nov 2025, 22:33 UTC

Tulu

AMD Beats Earnings. The Stock Still Slides. -- Barrons.com

4. nov 2025, 22:29 UTC

Tulu

Ashland 4Q Adj EPS $1.08 >ASH

4. nov 2025, 22:29 UTC

Tulu

Ashland Sees FY26 Adjusted EPS Up More Than Double Digits >ASH

4. nov 2025, 22:28 UTC

Tulu

Ashland Sees FY26 Sales $1.84B-$1.91B >ASH

4. nov 2025, 22:27 UTC

Tulu

Ashland 4Q Cont Ops EPS 73c >ASH

4. nov 2025, 22:27 UTC

Tulu

Ashland 4Q EPS 71c >ASH

4. nov 2025, 22:27 UTC

Tulu

Ashland 4Q Sales $478M >ASH

4. nov 2025, 22:23 UTC

Tulu

Ovintiv 3Q EPS 57c >OVV

4. nov 2025, 22:19 UTC

Market Talk

Canada Budget: Snap Election Talk Might Cool -- Market Talk

4. nov 2025, 22:16 UTC

Tulu

AMD Reports Sharply Higher Profits, Sales -- 2nd Update

4. nov 2025, 22:14 UTC

Omandamised, ülevõtmised, äriostud

Kennedy-Wilson Board Forms Special Committee to Evaluate Proposal

4. nov 2025, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Consortium: Not Interested in Selling Kennedy-Wilson Shares to Another Party

4. nov 2025, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Consortium: Able to Finance a Deal With Available Liquidity

4. nov 2025, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Consortium Owns About 31% of Kennedy-Wilson Stock on As-Converted Basis

4. nov 2025, 22:11 UTC

Tulu

Private-Credit Earnings Ease Investor Concern Over Market's Health -- Update

4. nov 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

Kennedy-Wilson Gets Proposal From CEO William McMorrow and Fairfax Financial Holdings

4. nov 2025, 22:10 UTC

Omandamised, ülevõtmised, äriostud

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- 2nd Update

4. nov 2025, 22:07 UTC

Tulu

Kinross Gold Raises Dividend to $0.035 >K.T

Võrdlus sarnastega

Hinnamuutus

Ventyx Biosciences Inc Prognoos

Hinnasiht

By TipRanks

50.67% tõus

12 kuu keskmine prognoos

Keskmine 12.4 USD 50.67%

Kõrge 21 USD

Madal 2 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Ventyx Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Ventyx Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.